Direct, Real-Time Visualization for a More Complete Resection1,2

the Gleolan Difference

See the Difference With Gleolan

regular-brain

Surgical Field Under White Light

When illuminating the surgical field under white light, it may be difficult to distinguish the tumor from surrounding healthy tissue.1

fluorescenting-brain

Surgical Field Under Blue Filter and Fluorescing Tissue

With Gleolan administered, when the surgical field is illuminated with white light using a blue filter, the high-grade glioma fluoresces red-violet, making it easier to identify.1

See How Gleolan Selectively Illuminates Glioma Cells

Administration of Gleolan leads to accumulation of the metabolite protoporphyrin IX (PpIX) in tumor tissue, permitting visualization of fluorescence during surgery.

SEE MORE

Gleolan Demonstrated Significant Improvement in EOR vs White Light1,3,4

  • ●64% of Gleolan patients had “completeness” of resection vs 38% in the control arm (P<0.0001)1,3,4
  • ●Surgical guidance with Gleolan is not limited by brain shift5
  • ●Gleolan may be used in adult suspected HGG patients of any age1

    In a clinical study, patients with suspected malignant glioma amenable to complete resection of contrast-enhancing tumor were randomly assigned to 20 mg/kg Gleolan for fluorescence-guided resection (n=176) or to conventional microsurgery with white light (n=173). A primary endpoint was the number of patients without contrast-enhancing tumor on early MRI (within 72 hours after surgery for resection).3
White_Light_Vs_Gleolan_Chart
>95%

Gleolan achieved a positive predictive value (PPV) for identification of malignant tissue across all studies1,3,6,7

EOR, extent of resection; MRI, magnetic resonance imaging

Key Benefits

See the Difference

check

Indicated for use in suspected WHO Grade III and IV glioma1

check

Surgeons using fluorescence-guided surgery with Gleolan demonstrated significant improvement in extent of resection vs white light1

check

Facilitates real-time visualization of suspected WHO Grade III and IV glioma2

check

Not limited by brain shift5

check

>95% Positive Predictive Value (PPV) for identification of malignant tissue1,3,6,7

check

Negative Predictive Value (NPV) varies based on sampling location8

check

Compatible with other technologies used during resection9

check

Rates of long-term neurologic complications in procedures that used Gleolan fluorescence-guided surgery vs white light are similar4

Gleolan Is Generally Safe and Well-Tolerated

Supported by data from 5 open-label clinical trials on 527 patients1:

  • ●Adverse reactions occurring in >1% of patients the week following surgery were pyrexia, hypotension, nausea, and vomiting1
  • ●Easy-to-administer oral dosing 2-4 hours before anesthesia1
  • ●Recognized in AANS/CNS, NCCN, ESMO and EANO guidelines for the treatment of glioma10-13
  • ●5-ALA has been used in more than 200,000 patients in over 46 countries14

Due to risk of phototoxic reactions, do not administer phototoxic drugs (St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines) and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after oral administration of Gleolan.

Please see Full Prescribing Information for additional important safety information.

doctor hospital team medical document health medicine_507599302

References

  1. Gleolan Prescribing Information.
  2. Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77(5):663-673.
  3. Medical Imaging Drugs Advisory Committee. FDA Briefing Package; May 10, 2017. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/medicalimagingdrugsadvisorycommittee/ucm557138.pdf.
  4. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
  5. Widhalm G. Intra-operative visualization of brain tumors with 5-aminolevulinic acid-induced fluorescence. Clin Neuropathol. 2014;33(4):260-278.
  6. Stummer W, Tonn JC, Goetz, C, et al. 5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery. 2014;74(3):310-320.
  7. Nabavi A, Thrum H, Zountsas B, et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery. 2009;65(6):1070-1077.
  8. Díez Valle R, et al. J Neurooncol. 2011;102:105-113.
  9. Schucht P, et al. Neurosurgery. 2012;71:927-936.
  10. Patrick HH, Sherman JH, Elder JB, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults. J Neurooncol. 2022;158(2):167-177. doi: 10.1007/s11060-021-03881-w
  11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 3.2026. August 17, 2026. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
  12. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G; ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii93-iii101.
  13. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z
  14. Data on file, NX Development Corp.
Prescribing Resource

Important Safety Information

Contraindications

Do not use Gleolan in patients with:

  • hypersensitivity to aminolevulinic acid (ALA) or porphyrins
  • acute or chronic types of porphyria

Warnings and Precautions

Due to the risk of phototoxic reactions, do not administer phototoxic drugs and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

Adverse Reactions

Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting.

Nervous system disorders occurred in 29% of patients within the first week after surgery and events occurring in >1% of patients included: aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in <1% of patients in the first 6 weeks after surgery. In a randomized clinical trial, the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to ALA fluorescence arm compared to the control arm. An imbalance was notable for the adverse events aphasia, ataxia, convulsion and hemianopsia and is likely related to the higher amount of brain resection performed in the ALA arm. At longer follow up periods, the numbers between the two arms appeared similar.

Worsening of >2 Common Toxicity Criteria grades in alanine aminotransferase and gamma-glutamyl transferase occurred in 15.8% and 11.6% of patients, respectively, within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal for each parameter. At 6 weeks, these measurements remained elevated in 2.9% and 7.5% of patients, respectively. There were no cases of liver failure.

Drug-Drug Interactions

See information under Warnings and Precautions regarding phototoxic reactions.

Please see Full Prescribing Information

For medical inquiries, please contact Medical Affairs at medicalaffairs@nxdevcorp.com

Reference

1. Gleolan Prescribing Information.